Home/ Stocks/ ALNY

Alnylam Pharmaceuticals, Inc.

ALNY XNAS

$308.05 +0.00 (+0.00%) ▲ 15-min delayed

Open

N/A

High

N/A

Low

N/A

Volume

N/A

Market Cap

$40.67B

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway in cells that enables sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 2.5K Website →

Key Financials

Period	Revenue	Net Income	EPS
TTM 2025	$3.71B	$313.75M	$2.39
FY 2025	$3.71B	$313.75M	$2.39
Q3 2025	$1.25B	$251.08M	$1.91
Q2 2025	$773.69M	$-66,277,000	$-0.51

TickerDaily Coverage

Why Is Vir Biotechnology, Inc. Common Stock (VIR) Stock Up 71.4% Today?

Market News Alex Chen · Feb 24, 2026

Vir Biotechnology (VIR) stock rocketed 71.4% to $7.43, posting one of the day's largest biotech...

View All Coverage →

Get ALNY Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Alnylam Pharmaceuticals, Inc..

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.